BerandaN1BI34 • BVMF
add
Neurocrine Biosciences Bdr
Tutup sebelumnya
R$34,41
Rentang tahun
R$25,64 - R$44,95
Kapitalisasi pasar
11,45Â M USD
Volume Rata-Rata
19,00
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 572,60Â jt | 11,12% |
Biaya operasional | 276,50Â jt | 13,74% |
Laba bersih | 7,90Â jt | -81,80% |
Margin laba bersih | 1,38 | -83,61% |
Penghasilan per saham | 0,70 | -41,67% |
EBITDA | 31,30Â jt | -71,93% |
Tarif pajak efektif | 46,26% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 943,50Â jt | -22,06% |
Total aset | 3,69Â M | 6,20% |
Total liabilitas | 1,15Â M | 6,05% |
Total ekuitas | 2,54 M | — |
Saham yang beredar | 98,97 jt | — |
Harga terhadap nilai buku | 1,34 | — |
Tingkat pengembalian aset | 1,60% | — |
Tingkat pengembalian modal | 1,94% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 7,90Â jt | -81,80% |
Kas dari operasi | 64,80Â jt | -50,27% |
Kas dari investasi | 14,20Â jt | 125,82% |
Kas dari pembiayaan | -117,90Â jt | -268,67% |
Perubahan kas bersih | -38,90Â jt | -126,79% |
Arus kas bebas | 28,91Â jt | -88,50% |
Tentang
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Didirikan
1992
Kantor pusat
Situs
Karyawan
1.800
